Fierce Biotech

Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.
Seeking Alpha

Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India

Jan. 31, 2024 7:02 AM ETTrinity Biotech plc (TRIB) Trinity Biotech will host a conference call on Wednesday, January 31 at 8:30 a.m. EST to discuss its recent Waveform acquisition. To access the call, please dial 1-877-407-0784 (domestic) or 1-201-689-8560 ...
The Business Journals

Bayer’s global head of biotech, Jens Vogel, leaving company

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min In the four years of his second ...
FierceBiotech

Bayer-partnered Azitra hopes to apply $7.5M IPO proceeds to near-clinical dermatology pipeline

Bayer-partnered Azitra will use the proceeds of a $7.5 million IPO to push its engineered bacterial treatments for skin conditions into the clinic. The Connecticut-based biotech’s pipeline is based on a library of about 1,500 bacterial strains that the ...
Seeking Alpha

Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer

DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on its development and ...
The Business Journals

Biotech signs deal with Bayer worth up to $547M

Dominique Verhelle is the co-founder and CEO of NextRNA Therapeutics. From the Boston Business Journal. NextRNA Therapeutics, a startup that aims to harness the potential of long non-coding RNA, has landed its first pharma deal. The Boston biotech ...
FiercePharma

Bayer christens $250M cell therapy 'launch facility' in Berkeley

Despite the promise of cell therapies, manufacturing the personalized medicines at scale has been a limiting factor for many companies. Now, as BlueRock Therapeutics advances its lead prospect, its parent company Bayer is ready to kick production into high ...
Benzinga.com

Bayer Seeks European Approval For Third Indication For Cancer Drug Darolutamide

On Monday, Bayer AG (OTC:BAYRY) submitted an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation ...
STAT

Bayer’s not breaking up. At least not yet

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with news of another biotech megaround, the potential next big thing from Novo Nordisk, and an ...